Risk Capital Partners, today announces that it has bought a majority stake in Xstrahl, a medical devices business that designs and delivers effective clinical and research solutions to advance radiation oncology.
Xstrahl is a leading designer and manufacturer of superficial orthovoltage X-ray systems used in the treatment of cancers and dermatological disorders, as well as a pioneer in the development of advanced X–ray systems for pre-clinical radiation biology research. For over 15 years, Xstrahl medical systems have reliably supported healthcare professionals and patients in over 500 clinics around the world.
Risk Capital Partners is supporting the existing management team led by CEO Adrian Treverton. The business is being acquired from the previous CEO, Martin Robinson, who has retired.
The company is headquartered in Britain and has facilities in the US. The majority of its production is exported to over 25 countries. Its customers are mainly hospitals and laboratories. It both manufactures and provides services directly and via distributors.
Adrian Treverton said: “I am excited by the opportunity to lead the buyout of Xstrahl, supported by Luke Johnson and Risk Capital Partners. Their entrepreneurial approach resonated with our management team. Our intention is to continue to grow Xstrahl, through innovation and close collaboration with our customers.”
Luke Johnson said: “Xstrahl is a global market leader in both its niche medical, and pre-clinical research markets. It has a highly creative and driven management team and we look forward to contributing to the vital work of treating cancers. Xstrahl plans to grow both organically and via strategic acquisitions in medical devices and equipment.”